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ErbB2Members of the epidermal growth factor (EGF) family bind to ErbB (EGFR) family receptors which play an
important role in the regulation of various fundamental cell processes including cell proliferation and
differentiation. The normal rodent kidney has been shown to express at least three members of the ErbB
receptor family and is a major site of EGF ligand synthesis. Polycystic kidney disease (PKD) is a group of
diseases caused by mutations in single genes and is characterized by enlarged kidneys due to the formation of
multiple cysts in both kidneys. Tubule cells proliferate, causing segmental dilation, in association with the
abnormal deposition of several proteins. One of the ﬁrst abnormalities described in cell biological studies of
PKD pathogenesis was the abnormal mislocalization of the EGFR in cyst lining epithelial cells. The kidney
collecting duct (CD) is predominantly an absorptive epithelium where electrogenic Na+ entry is mediated by
the epithelial Na+ channel (ENaC). ENaC-mediated sodium absorption represents an important ion transport
pathway in the CD that might be involved in the development of PKD. A role for EGF in the regulation of ENaC-
mediated sodium absorption has been proposed. However, several investigations have reported contradictory
results indicating opposite effects of EGF and its related factors on ENaC activity and sodium transport. Recent
advances in understanding how proteins in the EGF family regulate the proliferation and sodium transport in
normal and PKD epithelial cells are discussed here. This article is part of a Special Issue entitled: Polycystic
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Polycystic kidney disease (PKD) is a common genetic disease that is
associated with a high morbidity and mortality [1–6]. Autosomal
dominant (ADPKD) and autosomal recessive (ARPKD) polycystic kidney
diseases are characterized by the progressive growth and expansion of
cysts or dilatation of collecting ducts (CD), respectively, that ultimately
destroy the normal renal parenchyma. ADPKD is one of themost common
monogenic diseases and in 50% of cases results in end-stage renal disease
(ESRD) [4,7]. ARPKD is a rare genetic disorder and typically presents inuteroorduring theneonatal period.ADPKD is causedbymutation in PKD1
or PKD2genes.Mutation in the PKHD1gene is responsible forARPKD [4,8].
At ﬁrst glance, it seems that the three proteins polycystin-1 (PC-1),
polycystin-2 (PC-2) (encoded by PKD1 or PKD2, respectively), and
ﬁbrocystin (encoded by PKHD1) are involved in cyst formation and
mightbe regulatedby similarmechanisms. There are, however, important
differences that suggest that regulation of ADPKD and ARPKD are more
complicated than anticipated [9]. In ADPKD, cysts, which can arise from
any tubular segment, sprout from the nephron and no longer commu-
nicate with the tubule from which they originate. The majority of cystspolycystic kidney disease; ARPKD, autosomal recessive polycystic
al growth factor; EGFR, epidermal growth factor receptor; ENaC,
nding EGF; HFCT, human fetal collecting tubule; Isc, short circuit
ycystin-1; PC-2, polycystin-2; PI3-kinase, phosphatidylinositol 3-
r tyrosine kinase; SD, Sprague-Dawley; SH2, Src homology domain
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lumen [6,10]. In contrast, cysts in ARPKD are dilated CDs that remain
contiguous with the remaining nephron, allowing urine to continue to
ﬂow through the collecting system [6,11].
The CD is a ﬁnal site of renal regulation of Na+ and water balance.
Within the CD, Na+ diffuses from the lumen into principal cells
through the epithelial Na+ channel (ENaC) and is extruded at the
basolateral membrane in exchange for uptake of K+ by the Na/K-
ATPase. Cellular proliferation and ﬂuid secretion can be accelerated by
growth factors such as epidermal growth factor (EGF). EGF is a small
mitogenic protein that is thought to be involved in mechanisms such
as normal cell growth. ErbB receptors have been recognized as targets
in anticancer therapy and are now used in the treatment of breast and
colon malignancies. Other than tumor biology, EGF signaling is
critically involved in renal electrolyte homeostasis [12]. Moreover,
EGF plays an important role in the expansion of renal cysts. Cyst
growth is the result of proliferation of incompletely differentiated
epithelial cells and accumulation of ﬂuid within the cysts. Epithelial
cells from cysts from patients with both ADPKD and ARPKD are
unusually susceptible to the proliferative stimulus of EGF [6].
Moreover, cyst ﬂuids from these patients contain mitogenic concen-
trations of EGF, and this EGF is secreted into the lumens of cysts in
amounts that can induce cell proliferation [13]. It was ﬁrst shown that
EGF is an important mediator of the proliferative abnormality seen in
cyst formation in human ADPKD and that this involves a mislocaliza-
tion of the EGFR to the apical epithelial cell membranes [13].
Subsequent studies found this to be a common feature of PKD,
being observed not only in human ADPKD and ARPKD, but also in a
variety of spontaneously occurringmousemodels of ARPKD, as well as
mouse models derived by targeted mutations of genes responsible for
ADPKD. Here we discuss recent results supporting functional inter-
actions between EGF family proteins, proliferation and sodium
transport in normal and PKD cells, as well as detailing the molecular
mechanisms underpinning such interactions and discuss the biolog-
ical consequences of these regulations. Hence we aim to provide
critical insight into the physiological control of cell proliferation and
ion channel function by EGF and its related growth factors.
2. ErbB family
The epidermal growth factor receptor (EGFR) family, also known as
ErbB receptors, consists of four transmembrane receptors belonging to
the receptor tyrosine kinase (RTK) superfamily and includes EGFR
(ErbB1/HER-1), ErbB2 (neu/HER-2), ErbB3 (HER-3), and ErbB4 (HER-4)
[14]. The gene symbol for EGFRs, ErbB, originates from the name of a
viral oncogene towhich these receptors are homologous: Erythroblastic
Leukemia Viral Oncogene. EGFRwas the ﬁrst discovered RTK [15]. Since
then, EGFR (ErbB1/HER-1) is the best characterized and best known
ErbB receptor. Most of the principles and paradigms that underlie the
action of RTKwereﬁrst established for the EGFR [14,16]. In the following
discussion, we use the term "ErbB receptors" for the whole ErbB family
and the term "EGFR" in description of experiments where only ErbB1
(EGFR/Her-1) is examined.
EGFR as well as other ErbB receptors is a transmembrane receptor
consisting of an extracellular ligand-binding domain with conserved
two cysteine-rich domains necessary for ligand binding; a single
membrane-spanning domain which has a passive role in signaling and
functions as an “anchor” of receptor in plasma membrane [17] and a
cytoplasmic protein tyrosine kinase domain, where six tyrosine
autophosphorylation sites are located. After ligand binding, ErbB
receptors dimerize, which is a required critical step for intrinsic RTK
to be activated and speciﬁc tyrosine-containing residues become
autophosphorylated [18]. Phosphorylated ErbB receptors can recruit
different adapter proteins with Src homology domain-2 (SH2) or
phosphotyrosine-binding domains (PTB) [19]. Signals from dimerized,
activated ErbB receptors lead to activation of multiple intracellularsignal transduction pathways including cell growth, proliferation,
survival/decreased apoptosis, migration, etc. Depending on the pairing
of ErbB family receptors (homodimers or heterodimers), there can be
downstream stimulation of different combinations of signaling path-
ways [20].
Although EGFR is the predominant ErbB receptor expressed in the
normal adult mammalian kidney tubule, ErbB2 and ErbB4 have also
beendetected in developingureteric buds [21,22]. However,major roles
for ErbB2, ErbB3 and ErbB4 in neural and cardiac development are
demonstrated in null mice by embryonic lethality at embryonic day (E)
10 prior to the onset ofmetanephric development [21].We have shown
recently that all ErbB receptors are expressed at least at low levels in
cultured principal mpkCCDc14 cells. However, ErbB2 is the most
predominant member of the ErbB family in these cells [23]. Both
ErbB2 and ErbB4 have been detected in adult human and rat CDs,
respectively [24].We have recently also detected ErbB2 in adult rat CDs.
Fig. 1 shows representative immunohistochemistry staining for ErbB2 at
40× and 100× magniﬁcations in a cortical section of Sprague-Dawley
(SD) rat kidneys. Immunohistochemistry analysis was performed as
described previously [23,25]. A negative control (left) (stained with
secondary antibodies in the absence of primary antibodies) is also
shown.Additional controls (without primary and secondary antibodies)
were also negative (data not shown). As clearly seen in Fig. 1, ErbB2 is
highly expressed in the CDof SD rat kidney and is localizedmostly at the
basolateral surface.
ErbB receptors are predominantly located at the basolateral
surface of normal adult polarized tubule epithelial cells but on the
apical surfaces of fetal ureteric bud-derived collecting ducts
[187,188,191]. ErbB ligands have autocrine properties, which may
explain preferential co-localization of the ligands and their receptor
at the basolateral surface. Development of epithelial cell polarity
requires a well orchestrated, domain-speciﬁc segregation of lipids,
membrane proteins, and cytoskeleton. Intracellular transport to the
plasma membrane is regulated in part by intrinsic signals recognized
at different steps in polar sorting pathways. A number of polar sorting
determinants have now been identiﬁed in membrane proteins, and
principles for both sequence and structural requirements are
beginning to emerge. For example, a 23-amino acid segment located
near the cytoplasmic face of the membrane spanning domain
(residues Lys-652 to Ala-674) is necessary and sufﬁcient for targeting
EGFR from the trans-Golgi network directly to the basolateral plasma
membrane [26,27]. ErbB receptor localization and regulation will be
discussed further below.
3. EGF and its related growth factors
Regulation of ErbB receptor function is controlled by their ligands,
members of the EGF-related peptide growth factor family [28]. All EGF
family members, like many other growth factors, are derived from
membrane-bound precursor proteins [29,30]. There are over 12
ligands that can bind ErbBs and induce dimerization of distinct
functional receptor pairs. EGF, transforming growth factor-α (TGF-α),
and amphiregulin are speciﬁc for EGFR and primarily induce the
formation of EGFR/EGFR homodimers and EGFR/ErbB2 heterodimers
[31]. Betacellulin, heparin-binding EGF (HB-EGF), and epiregulin can
bind to either EGFR or ErbB4. Neuregulins-1 and -2 can bind both
ErbB3 and ErbB4; neuregulins-3 and -4 are speciﬁc only for ErbB4.
Currently, no known ligands have been identiﬁed for ErbB2 homo-
dimers. However, ErbB2 is the preferred heterodimerization partner
of other ErbB family members and ErbB2-containing heterodimers
have the strongest signaling output [32,33]. The sequence of the ErbB3
catalytic domain suggests that this receptor does not have RTK activity
[34]. Thus, ErbB3 may function as a platform for heterodimerization
and subsequent trans-phosphorylation by other members of the ErbB
family. Hence ErbB2 and ErbB3 can be activated through hetero-
dimerization [34,35]. It was proposed recently that the kinase domain
Fig. 1. ErbB2 expression in rat kidney tissue. Representative immunohistochemical staining for ErbB2 detection in kidney cortical sections of Sprague-Dawley rat. Original
magniﬁcations are 40× (b) and 100× (c). Scale bars are 50 μm. Negative control (a) (stained with secondary antibodies in the absence of primary antibodies) at 40× is also shown.
The kidney was ﬁxed for 24 h in zinc formalin and processed for parafﬁn embedding as described previously [23,25]. The kidney sections were cut, dried and deparafﬁnized for
subsequent labeled streptavidin-biotin immunohistochemistry. Tissue sections were incubated for 90 min in a 1:250 concentration of anti-ErbB2 (Cat. #ab2428; Abcam, Inc.,
Cambridge, MA).
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appears to be ~1000-fold weaker than for EGFR but may be sufﬁcient
for receptor trans-phosphorylation in the context of an ErbB
heterodimer [36].
ErbB ligands exist as inactive transmembrane precursors and
need the proteolytic cleavage of their ectodomain to be released as
mature soluble ligands. All EGF family members are synthesized as
membrane-anchored precursors that can be processed by speciﬁc
metalloproteases to release soluble bioactive factors from the cell
surface. This cleavage is performed by ADAM (a disintegrin and
metalloprotease) family members [37–40] and tightly regulated by
different factors. For example, intravenous angiotensin II (Ang II)
infusion induced ADAM17 redistribution to the apical cell membrane,
followed by release of TGF-α and activation of the EGFR [41]. This led
to the development of glomerulosclerosis, interstitial inﬁltration of
monocytes, ﬁbrosis, and proteinuria. ErbB receptor ligands are cleaved
by multiple ADAMs, including ADAM9, 10, 12, 15, 17, and 19. In
addition to these ErbB receptor ligands, many ADAMs have multiple
substrates, and thereby appear to be involved in various signaling
pathways and cellular functions [40]. A role for matrix metallopro-
teinases (MMPs) in cleaving of ErbB receptor ligands is also proposed
[42,43]. MMPs are a large family of zinc-contained proteolytic
enzymes that have the capability to degrade extracellular matrix
proteins [44]. It was shown recently that MMP9 protects mesenchy-
mal cells from apoptosis during kidney development and stimulates
ureteric bud branching morphogenesis, most likely by releasing the
soluble form of stem cell factor, suggesting that normal renal
development requires MMP9 [45].
4. Activation of ErbB receptors and physiological functions
Addition of ErbB receptor ligands to tubular cells promotes
several biological responses, including cell proliferation. The phys-
iological role of ErbB receptors and particularly of EGFR and ErbB2 is
well established, especially in cancer. Activating mutations and
overexpression of members of the ErbB family have been implicated
in a variety of cancers, including mammary and squamous carcino-
mas, glioblastomas, lung cancer as well as other malignant diseases
[14,46,47]. The role of ErbB family members in renal development,
physiology and pathophysiology is also well recognized [21]. Under
physiological conditions, ErbB activation appears to play an impor-
tant role in the regulation of renal hemodynamics and electrolyte
handling by the kidney, while in different pathophysiological states,
ErbB activation may mediate either beneﬁcial or detrimental effectsto the kidney [21]. ErbB signaling is critically involved in cell
signaling, cell growth, proliferation, and renal electrolyte homeo-
stasis. Most of the ErbB family ligands are expressed in the kidney.
For example, HB-EGF is synthesized in the proximal tubule, EGF in
thick ascending limb of Henle's loop (TAL) and distal convoluted
tubule (DCT), and TGF-α in the DCT and CDs [48,49]. However, EGF
and its related growth factors are present in the lumen at levels
several orders higher than in plasma. As described above, ErbB
receptors are expressed at the basolateral surfaces of normal adult
kidneys. Thus, ErbB receptors are not accessible to their ligands in the
lumen. This may serve as a protective mechanism for the distal
nephron. One of such examples is mislocalization of ErbB receptors in
PKD which will be discussed below. Another potential mechanism is
a disturbance of epithelial cellular integrity. Following tubular injury,
tight junctions can be disrupted and thus allow ErbB receptor ligands
to traverse to the basolateral surface and consequently activate
corresponding receptors. It was shown that EGF via the Raf-1/ERK1/2
pathway regulates the content and distribution of claudins [50,51],
proteins that are the most important components of the tight
junctions, where they establish the paracellular barrier that controls
the ﬂow of molecules in the intercellular space between epithelial
cells [52]. HB-EGF has also been shown to play an important role in
the regulation of tight junction proteins and transepithelial resis-
tance [53,54].
As discussed above, activation of ErbB receptors is accomplished
through ligand binding to the extracellular domain, followed by
receptor homo- or heterodimerization and tyrosine transphosphoryla-
tion. Combinatorial interactions are very important in ErbB receptor
polarization and downstream signaling since ErbB homodimers and
heterodimers differ in their biological properties [55].
Once activated by site-speciﬁc phosphorylation, ErbB receptors
serve as molecular integrators through either direct phosphorylation of
target molecules or by serving as scaffolds for adaptor proteins.
Activation of ErbB receptors leads to initiation of various signaling
cascades. The great diversity of ligands and receptor dimer pairs allows
for the activation of numerous signaling pathways that coordinately
regulate complex processes including developmental growth control
and adult homeostasis. Fig. 2 demonstrates one of such examples when
ErbB receptor is phosphorylated and misslocalized during pathophys-
iological conditions. This ﬁgure shows immunohistochemistry staining
for phosphorylated ErbB2 (pErbB2) at 40× in a cortical section of SD rat
kidneys and in PCK rats (Charles River Laboratories International, Inc.,
Wilmington,MA) at40×and100×magniﬁcations. ThePCK rat harbours
an autosomal recessive Pkhd1 gene mutation and is a model of ARPKD
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compared to normal rat kidney and is localized at the apical membrane
of CDs (Fig. 2).
5. PKD
Polycystic kidney diseases (PKD) are a group of inherited disorders
characterized by development of renal cysts. Of these, the most
common lethal monogenic forms are ADPKD, characterized by
progressive development of ﬂuid-ﬁlled cysts; and themainly infantile,
ARPKD [4,6,11,57]. ADPKD is inherited as a dominant trait, initiated in
utero but usually leading to onset of renal failure in mid-life. It is
characterized by early separation of focal spherical cysts from all
segments of the nephron and progressive expansion by cell
proliferation and ﬂuid secretion throughout life. In contrast, ARPKD
is inherited as a recessive trait, often lethal in the perinatal period, and
is characterized by ecstatic distension of CDs to form numerous
spindle-shaped renal cysts [4–6,11,58]. Because of these differences,
ADPKD and ARPKD are treated as two distinct diseases in clinical
practice [59].
5.1. ADPKD
ADPKD is one of the most common monogenetic diseases affecting
humans [60] and occurs approximately in 1 in 800 live births. Recent
advances in ADPKD are thoroughly reviewed by Torres and Harris [5].
The primary phenotype of ADPKD is the progressive development in
both kidneys of multiple ﬂuid ﬁlled cysts, which eventually result in
ESRD [6]. Two genes have been shown deﬁnitively to result in ADPKD
when mutated: PKD1, which accounts for 85%, and PKD2, which is
responsible for 15% [3]. The PKD1- encoded protein, polycystin-1 (PC-1)
is a large (~460 kDa) membrane protein with a long, modular
extracellular N-terminal component capable of protein-protein inter-
actions, 11 transmembrane domains, and a short (~200 amino acid)
intracellular C-terminal domain [61] which is capable of physical
interactions with the PKD2-encoded polycystin-2 (PC-2), proteins of
focal adhesion and cell-cell adherent junctional complexes aswell as the
α1-subunit of Na,K-ATPase [62,63]. mRNA and protein expression
studies have shown that PC-1 is developmentally regulated and highly
expressed in fetal kidneys in ureteric bud-derived CD [64–66]. On the
basis of its predicted structure and functional features, PC-1 is
postulated to be a plasma membrane receptor involved in cell–cell
interaction and the regulation of several signaling pathways linked toFig. 2. pErbB2 expression in normal and cystic rat kidney tissue. Representative immunohis
(a) and PCK (b, c) rats. Original magniﬁcations are 40× and 100× (scale bars: 50 μm). Tissue
Cat. #2243; Cell Signaling Technology, Inc., Boston, MA).cell proliferation [6,67–69]. The PC-1 C-terminal domain also contains
speciﬁc tyrosine (Y) and serine (S) sites for phosphorylation. PC-1 and
PC-2 interact physically [62,65,70–73] and form a Ca2+-permeable non-
selective cation channel when expressed heterologously [63,74,75].
Furthermore, it was recently shown that PC-1/PC-2 complex regulates
pressure sensing [76]. A newly identiﬁed coiled-coil domain located in
the C-terminus of PC-2 has been shown to mediate dimerization of the
C-terminus of PC-2 and recognition of PC-1 [77] and is proposed to be
essential for assembly and function of heteromeric polycystin com-
plexes [78].
PC-2, also called TRPP2, belongs to the transient receptor potential
(TRP) superfamily of ion channels [79–81]. PC-2 has six transmem-
brane domains, a pore forming region, and cytoplasmic N- and C-
terminal tails [81–83]. In addition to forming a heteromeric complex
with PC-1, PC-2 has also been proposed to form heteromeric channels
with TRPV4 and TRPC1 [84–86]. It was shown that PC-2 and TRPV4
form a mechanical and thermal sensor in cilia and suggested that
TRPV4 is the mechanically sensitive component of the complex [84].
The PC-2/TRPC1 heteromeric channel is activated in response to GPCR
activation and shows a pattern of single-channel conductance,
amiloride sensitivity and ion permeability distinct from that of PC-2
or TRPC1 alone [85]. Kobori et al. using atomic force microscopy
recently proposed that PC-2 and TRPC1 form a hetero-tetramer with a
2:2 stoichiometry and an alternating subunit arrangement [86].
Several protein–protein interactions have been reported previously
between TRP channels, most of them are known to occur between
members of the same group. Similarly to PC-2/TRPC1 and PC2/TRPV4
complexes, we have shown recently that members of other
subfamilies of TRP channels, TRPA1 and TRPV1, can assemble into a
complex on the plasmamembrane and that TRPV1 inﬂuences intrinsic
characteristics of the TRPA1 channel [87].5.2. ARPKD
ARPKD is a hereditary renal cystic disease in infants and children
affecting the kidneys and liver and occurs in approximately 1 in
20000 live births. Renal failure and hepatic ﬁbrosis develop in most
babies who survive the perinatal period. The disease is characterized
by the expansion and elongation of collecting tubules into multiple
small cysts [6]. ARPKD is caused by mutations in the PKHD1
(polycystic kidney and hepatic disease 1) gene [88–90]. The PKHD1-
encoded protein, ﬁbrocystin-1 (polyductin) spans the cell membrane
of kidney cells and is developmentally regulated. Based on ﬁbrocystintochemical staining for pErbB2 detection in kidney cortical sections of Sprague Dawley
sections were stained with anti-pErbB2 (Phospho-HER2/ErbB2 (Tyr1221/1222); 1:100;
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physically interact with PC-2, it is thought to act as a mechano-
receptor, receiving external signals and initiating various intracellular
signaling processes. This protein alsomay be involved in adhesion and
proliferation. However, exact role of ﬁbrocystin is unknown. Although
the human genome contains a PKHD1 homolog, PKHDL1, this is not
ARPKD-associated but is thought to be an ancestral variant of PKHD1
[91]. Fibrocystin-1 has been shown to be associated with the basal
bodies/primary cilia of epithelial cells [92–94] and co-localized with
PC-2 in vitro and in vivo [95–97]. We have shown recently that PKHD1
mutation in human ARPKD is associated with alterations in cell
spreading, matrix adhesion, and migration due to abnormalities of
focal adhesion protein (FAK, c-Src, paxillin) content, distribution, and
activation by site-speciﬁc phosphorylation [98].
The overexpression and abnormally located ErbB receptors on the
apical surface of cyst lining epithelia in human and murine models of
ARPKD have been shown speciﬁcally to bind with high afﬁnity EGF/
TGF-α. Overexpressed ErbB receptors autophosphorylate and gener-
ate mitogenic signals in response to growth factors [99–102].
However, surprisingly, neither overexpression nor mislocalization of
EGFR was seen in PCK rats, the only current genetically orthologous
rodent model of ARPKD. Moreover, the speciﬁc inhibitors of EGFR
(ErbB1), EKI-785 and EKB-569, had no effect on renal cystic
progression or ﬁbrocystic liver disease [103]. Subsequently, high
expression levels of ErbB2 were observed in the renal cystic epithelia
in PCK rats [104]. More recently, we have not only observed that
ErbB2 is predominantly localized on the basolateral surface in the PCK
rats (data not shown) but also shown that phosphorylated pErbB2 is
abnormally expressed and mislocalized on the apical surface of cystic
epithelia (Fig. 2) compared to normal rat CDs.
6. EGF-mediated proliferation
EGF-ErbB receptor-mediated interactions are key elements in
renal tubular cell proliferation, not only in normal kidneys but also in
cyst formation and enlargement. Activation of the intrinsic kinase
domain results in phosphorylation of speciﬁc tyrosine residues within
the cytoplasmic tail [105] that serve as docking sites for a range of
proteins, the recruitment of which leads to the activation of
intracellular signaling pathways [105,106]. The duration and strength
of intracellular signaling of ErbB receptors depend on speed of down-
regulation by internalization, as well as the ratio of receptors that are
targeted for recycling or degradation. Homodimers of EGFR have a
signal which does not last long, in part due to receptor down-
regulation and degradation after ligand-dependent activation [107].
EGF is a well-knownmitogen for normal renal epithelia, and has been
shown to hyperstimulate proliferation in ADPKD and ARPKD cystic
epithelia [13,108]. As mentioned above, EGF and EGF-reactive peptide
species are secreted into the apical medium of cultured ADPKD
epithelia, and high, potentially mitogenic concentrations have been
measured in cyst ﬂuids collected from ADPKD patients [6,13].
Increased expression of TGF-α has been observed in PKD cells
compared with normal kidney cells [109] and transgenic mice
overexpressing TGF-α develop cystic kidneys [110]. Abnormal
expression of amphiregulin and HB-EGF has also been reported in
both autosomal dominant and autosomal recessive PKD [13,108–110].
In non-orthologous murine models of ARPKD HB-EGF showed the
mostmarked activation of EGFR andwas seen on apical membranes of
cystic epithelia, while amphiregulin was ineffective and not on apical
membranes. These studies suggested that the relative potencies of
growth factors in the context of cyst expansion are a function of
membrane ligand bound/receptor trafﬁcking, as well as ligand
availability [111].
Ligand-induced activation of ErbB receptors can stimulate a variety
of intracellular pathways including PKC/AKT, PLCγ, MEK/Erk or c-Src.
Phosphorylation of EGFR at Y845 in the kinase domain is implicated instabilizing the activation loop, maintaining the active state of the
enzyme and providing a binding surface for substrate proteins. c-Src
binds to and phosphorylates EGFR at Y845 and is required for ErbB
family-mediated signaling and proliferation in normal cells as well as
in cystic renal epithelia [104,112,113]. It was also shown that
increased pY418-Src activity correlated with cystic expansion in BPK
mice and PCK rats and that inhibition of Src activity could attenuate of
renal cystic disease in these respective phenotypic and genotypic
rodent models of ARPKD [104].
Overexpression, constitutive activation, and abnormal location of
EGFR and ErbB2 receptors on the apical (luminal) surface of cyst lining
epithelia, together with secretion of soluble ligands by PKD cyst lining
epithelia, creates a sustained cycle of autocrine–paracrine stimulation
of proliferation in cysts [13,100,102,114]. A precisely controlled
balance between cellular proliferation and apoptosis is essential for
normal growth and differentiation of the kidney and maintenance of
normal renal structure. These fundamental processes are disturbed in
cystic kidneys [6,115]. Moreover, it was shown recently that EGFR
membrane polarity is regulated by multiple hierarchical sorting
pathways in renal epithelial cells and some of these pathways are
perturbed in the BPK ARPKD mouse model [116].
Another common feature in PKD kidneys is a failure to switch off
fetal genes and proteins, such as ErbB2, after completion of the
developmental period [187]. ErbB2 receptor which is highly expressed
in several human cancers, including renal carcinomas, aswell as in PKD,
can potentiate EGFR signaling by slowing down the internalization and
degradation of EGFR [117]. Although ErbB2 requires heterodimerization
with another ligand-bound ErbB family member, such as EGFR, to be
activated by autophosphorylation at Y1248 and Y1221/1222 [118],
heterodimers are not only the favored complexes. As noted above,
activation of ErbB2 is known to produce the strongest ErbB-related
intracellular signaling responses. The importance of the ErbB2 receptor
variant is further demonstrated both in cultured cells, where over-
expression and activation of ErbB2 enhances proliferation and migra-
tion [119–122] and in transgenic mice where overexpression of ErbB2
induces renal cyst formation [108,123].
7. EGF-mediated regulation of sodium transport in normal and
PKD cells
The epithelial Na+ channel (ENaC) is a member of the ENaC/Deg
channel superfamily [124–128]. ENaC activity is the rate-limiting step
for Na+ (re)absorption across many epithelia, including those in the
distal nephron, lungs and colon. Dysfunction and aberrant regulation of
this channel leads to a spectrum of diseases ranging from hypertension
and hypotension associated with improper renal Na+ conservation
and wasting, respectively, to respiratory syndromes linked to cystic
ﬁbrosis [129,130]. Moreover, several forms of congenital hypotension
and hypertension, such as pseudohypoaldosteronism and Liddle's
syndrome, respectively, result from ENaC dysfunction with the prior
being caused by loss of functionmutations in the channel and the latter
by gain of function mutations [131].
EGF family ligands regulate various epithelial channels, including
ENaC, TRPC5, TRPM6 and PC-2. As we discussed above, EGF and its
related growth factors have direct actions on the primary route of Na+
reabsorption in the distal nephron. This site of the nephron gives rise
to many of the cystic epithelial cells in PKD particularly in ARPKD
which appears to be limited to distal tubular cystic development
[6,10,132–134]. Activity of ENaC is the rate-limiting step in Na+
reabsorption at this site [125,126,128]. Thus, ENaC dysfunction has
been linked to a broad spectrum of human diseases including PKD
where it may have an important pathophysiological role at the very
earliest stages of the disease. Here wewill summarize recent advances
in the understanding of regulation of epithelial ion channels by EGF
family ligands in the normal and cystic kidney. This review will
certainly not be complete, in part due to the considerable bulk of data
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in advance to the authors of any relevant studies that we fail to
mention.
7.1. Role of EGF in regulation of ion channels in the kidney
EGF and its related growth factors are involved in regulation of
various epithelial ion channels in thekidney. For instance, EGF stimulates
store-operated Ca2+ channels in human mesangial cells through an
intracellular signaling mechanism involving tyrosine kinase and PKC
[135]. Later it was shown that EGF activates store-operated Ca2+
channels by a PLC-dependent but IP3 receptor-independent pathway
[136].
The TRP superfamily of signal-transduction-gated ion channels is
widely expressed in the kidney [79,137–139]. Bezzerides et al. have
shown that EGF stimulation rapidly induces TRPC5 channel translo-
cation to the plasma membrane. The small G protein Rac1 mediated
the rapid insertion of TRPC5 into the plasma membrane through
stimulation of PI(4)P 5-kinase and increased channel availability. The
authors proposed that rapid insertion of TRP channels may be a
general process of cells in response to stimuli that affect cell
morphology and perhaps, direction of movement [140]. We have
also shown that RhoA and Rac1, small G proteins in the Rho family
affect ENaC trafﬁcking [25,141–144]. However, a role of growth
factors in Rho-mediated increase of ENaC activity is not clear yet.
A role for ErbB receptor activation in the regulation of Mg2+
channels in the kidney has also recently been proposed. The
regulation of magnesium in the body principally occurs within the
kidney. Genetic analysis has revealed that the TRPM6 channel is
mutated in patients with primary hypomagnesemia and secondary
hypocalcemia [145,146]. Moreover, Groenestege et al. described a
mutation in the EGF gene, encoding pro-EGF, which is responsible for
a rare form of renal Mg2+ wasting, isolated recessive hypomagnese-
mia [147]. TRPM6 is a magnesium channel that is expressed in the
intestine and renal distal tubules. Two different laboratories studied
the effects of EGF on TRPM6 channels. Miwa and colleagues have
shown that EGF increased the phosphorylation of ERK1/2 and TRPM6
expression in renal epithelial NRK-52E cells. Furthermore, EGF
enhanced the inﬂux of magnesium. Thus it was proposed that the
phosphorylation of ERK1/2 may up-regulate TRPM6 expression and
magnesium inﬂux, resulting in an increase in cell proliferation with a
shift from G1 to S phase [148]. Recently, they have shown that the
ERK/AP-1-dependent pathway is involved in the transcriptional
regulation of TRPM6 expression [149]. Bindels and colleagues
reported that EGF-mediated stimulation of TRPM6 occurs via
signaling through Src kinases and the small GTPase Rac1, thereby
redistributing endomembrane TRPM6 to the plasmamembrane [150].
It is interesting that this effect was speciﬁc since stimulation of the
EGFR increased current through TRPM6 but not TRPM7 [150]. Recent
study showed that EGFR inhibitor erlotinib is capable of affecting
TRPM6 regulation and thereby altering Mg2+ handling in vivo.
Erlotinib can inﬂuence Mg2+ handling but its effect on the systemic
Mg2+ concentration seems less potent than that observed with
antibody-based EGFR inhibitors. Thus, these data suggest that typical
human dosages of erlotinib are unlikely to severely affect serumMg2+
concentrations [151].
7.2. EGF-mediated regulation of polycystins
PC-2 can be activated in response to EGF in the kidney epithelial
cell line LLC-PK1 [152]. PC-2 overexpression increases EGF-induced
inward currents in LLC-PK1 cells, while the knockdown of endogenous
PC-2 by RNAi or the expression of a pathogenic missense variant,
PKD2-D511V, blunts the EGF-induced response [152]. The physiolog-
ical relevance of EGF-induced activation of TRPP2 in LLC-PK1 cells was
supported by whole animal studies in which homozygous deletion ofthe EGFR gene resulted in cystic dilatation of CDs [70,153]. EGF-
induced activation of PC-2 occurred independently of store depletion
but required the activity of phospholipase C (PLC) and phosphatidy-
linositol 3-kinase (PI3-kinase). Interestingly, PC-2 interacted with
PLC-γ2 and colocalized in the primary cilium with EGFR and PIP2
[152]. The authors proposed that PC-2 is under negative regulation by
PIP2, which can be reversed by EGFR activation.
In addition, yeast two-hybrid screen analysis identiﬁed mDia1
(mammalian Diaphanous-related formin 1 protein) as a PC-2-
interacting protein [154]. mDia1 is a member of the small G protein
RhoA-binding-formin protein family that participates in cytoskeletal
organization, cytokinesis, and signal transduction. mDia1 functioned
as an intracellular, voltage-dependent regulator of PC-2. At resting
potentials, autoinhibited mDia1 bound to and blocked PC-2, whereas
at positive potentials activated mDia1 released the block on PC-2
leading to channel activation. EGF or membrane depolarization
activated PC-2 through the sequential activation of RhoA and
mDia1. The voltage-dependent block of PC-2 by mDia1 served two
physiologically relevant roles to underlie the activation mechanism
of PC-2 by EGF and to set the resting membrane potential of kidney
epithelial cells to its resting value by preventing constitutive activation
of PC-2 [155].
7.3. EGF and its related growth factor-dependent regulation of
ENaC-mediated sodium transport in principal cells
EGF has been known for almost two decades to regulate sodium
transport. However, several investigations have reported contradic-
tory results indicating opposite effects of EGF on ENaC activity and
sodium transport. EGF appears to affect sodium transport and ENaC in
a context-dependent manner: it increases sodium absorption in the
airways [156] and intestine [157], but decreases sodium transport in
the isolated and perfused rabbit CD [158–161], immortalized murine
CD mCT1 cells [162,163], in cystic ﬁbrosis JME/CF15 cells [164], in
Chinese hamster ovary (CHO) cells overexpressing ENaC subunits and
EGFR [165] and in Madin-Darby canine kidney cells [166,167].
Markadieu et al. demonstrated that EGF transiently increases sodium
transport in Xenopus laevis kidney A6 cells in a PI3-kinase-dependent
manner, and that this stimulation is increased by the inhibition of the
MAPK pathway [168].
Recently Liu et al. have proposed that ENaC shows a biphasic
response to EGF and TGF-α in A6 cells [169]. These authors also
showed that acute treatment with EGF and TGF-α enhanced ENaC
activity by increasing Po and that PI3-kinase was involved in the
activation of sodium transport [169]. Similarly, EGF via the small G
protein Rac1, acutely activates ENaC in alveolar epithelial cells [170].
However, chronic treatment with EGF and TGF-α inhibited ENaC
activity by decreasing the number of channels (N) in the plasma
membrane throughMAPK1/2 pathways [169]. Short-term blockade of
the MAPK1/2 has also been shown to down regulate both the basal
Na+ current and the aldosterone and vasopressin stimulated Na+
current in mpkCCDc14 principal cells. The authors proposed that the
activity of Na,K-ATPase but not that of ENaC was inhibited by MEK1/2
inhibitors in both unstimulated and aldosterone- or vasopressin-
stimulated CCDs [171]. Similarly, inhibitors of the MAPK1/2 cascade,
protected Na+ reabsorption from PKC, demonstrating that the
MAPK1/2 cascade, in some instances, plays a central role in down-
regulation of ENaC activity [172]. Furthermore, we have shown that
the small G protein K-Ras activates ENaC activity via PI3-kinase in
both heterologous and native principal cells [173–175]. K-Ras is an
aldosterone-induced protein and most likely its effect on ENaC is
mediated by this hormone [176–179]. However, K-Ras expression and
activity could also be regulated by growth factors such as EGF
[180,181]. Furthermore, it was proposed that EGFR is transactivated
by aldosterone [182]. For example, it was shown recently that
aldosterone-induced mesangial cell proliferation is mediated by
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ERK and PI3-kinase/Akt/mTOR/p70S6K1 signaling pathways [183].
However, it still remains to be shown whether K-Ras or other small G
proteins are involved in EGF-mediated regulation of ENaC activity.
Our recent data are consistent with the idea that EGF and its related
growth factors (TGF-α, HB-EGF and amphiregulin) have a biphasic
effect on sodiumabsorption in themammaliankidney as represented by
mpkCCDc14 cells and that inhibition ofMEK1/2 stimulates acute increase
and abolishes chronic decrease of sodium transport in response to EGF
action [23]. As shown in Fig. 3, addition of all four studied EGF family
growth factors to polarizedmpkCCDc14 principal cells with steady-state
basal transport rates signiﬁcantly increased Na+ reabsorption above
basal levels in a time-dependent manner. Signiﬁcant increases were
detectable after 30 min, the earliest time point measured, with a
maximum reached by 2 h. After 4 h of stimulation, a slow and
continuous decrease of Isc (short circuit current) was observed. Chronic
treatment ofmonolayerswith EGF and its related growth factors (added
basolaterally) leads to signiﬁcant inhibition of Isc. As illustrated in Fig. 3,
addition of the Na+ channel inhibitor amiloride (10 μM) at the end of
experiments to the apical bathing solution caused a rapid decrease in Isc.
Nearly all of thebasal Iscwas inhibitedbyamiloride. Thus, the addition of
EGF caused a transient increase in Isc followed by a chronic decline in Isc
and these effects were mediated by receptors located at the basolateral
membrane. The acute effect of EGF was mediated via PI3-kinase and
both phases were mediated by MEK1/2. Acute effect is most likely
mediated by changes in the channel's open probability and long-term
effect occurred due to the decrease of the number of active channels at0.0
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previously published in a different format [23].the plasmamembrane [23,169]. Furthermore, our study underlined the
critical role of ErbB2 in the regulation of sodium transport in these
collectingduct cells and suggested thatEGF inﬂuences ENaCand sodium
absorption via the ErbB2 receptor, most probably by forming ErbB2/
EGFR heterodimers [23]. Fig. 4 shows our favored possible model for
regulation of ENaC in normal CD monolayers by EGF family ligands. As
demonstrated in this ﬁgure, there are at least two independent
pathways involved in the regulation of ENaC. However, it is very likely
that other proteins are involved in regulation of ENaC. As we discussed
previously, Bezzerides et al. demonstrated that EGF stimulation rapidly
induces TRPC5 channel translocation to theplasmamembrane andRac1
mediates this insertion [140]. Bindels and colleagues also reported that
EGF-mediated stimulation of TRPM6 occurs via signaling through Src
kinases and Rac1 [150]. Importantly, Fujita and colleagues have
established that signaling cross-talk between Rac1 and the mineralo-
corticoid receptor modulates receptor activity and identiﬁed Rac1 as a
therapeutic target for chronic kidney disease[184,185]. Garvin's and
Helms’ laboratories also recently identiﬁed an important role for Rac1 in
NaCl-induced superoxide generation in the medullary thick ascending
limb[186] and in the alveolar epithelium[170]. Thus, small GTPase Rac1
is a probable effector of EGF and its related growth factors with respect
to ENaC activity. However, this hypothesis requires further studies.
7.4. Regulation of sodium transport in PKD cells
Since EGF and its related growth factors regulate ENaC activity, it is
possible that ENaC inhibition facilitates cyst formation in PKD [187].0.0
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coordinated interaction between ENaC and the cystic ﬁbrosis
transmembrane conductance regulator Cl- channel (CFTR) suggesting
the possibility that ENaC may play some role in cystic ﬁbrosis and
other disease processes associated with dysfunctional CFTR [188–
192]. Increased airway Na+ absorption in vivo caused airway surface
liquid volume depletion, increased mucus concentration, delayed
mucus transport and mucus adhesion to airway surfaces. Defective
mucus transport caused a severe spontaneous lung disease sharing
features with cystic ﬁbrosis [193]. The airway surface liquid volume
modulates the activity of ENaC by modiﬁcation of the serine protease-
protease inhibitor balance and alterations in this balance contribute to
excessive Na+ absorption in cystic ﬁbrosis [194]. It was shown that
the CFTR Cl- channel exists in apical membranes of human ADPKD
cells andmay play an important role in cyst formation or enlargement
[195]. Cl- currents in cultured ADPKD cells were activated by forskolin
and cAMP and had properties identical to those that characterized
CFTR [195]. Later Magenheimer et al. have shown that cAMP-
stimulated ﬂuid secretion occurs early in embryonic renal tubule
development in wild-type and PKD kidneys at the time when renal
cysts ﬁrst appear in ADPKD, suggesting that a cAMP-driven mecha-
nism may be involved in the initial stages of cyst formation in ADPKD
[196]. Moreover, CFTR inhibitors partially inhibited cyst growth and
preserved renal function in a mouse model of ADPKD [197]. However,
renal cyst formation in a murine model of ARPKD did not require
functional activity of CFTR [198].
In ADPKD, all the segments of the nephron are involved in forming
the ﬂuid-ﬁlled cysts. In ARPKD, dilated tubules rather than isolated
cysts are predominantly formed from the CD, which is the nephron
segment where ENaC plays a major role in the regulation of sodium
transport [199,200]. ENaC dysfunction associated with improper
handling of NaCl has been demonstrated in renal epithelial cells
from animal models and human ARPKD cell lines [201–204].Measurements of transepithelial 22Na transport performed on
monolayers of ARPKD and age-matched human fetal collecting tubule
(HFCT) cells revealed net Na+ absorption in both models. However,
ARPKD cells absorbed Na+ at a rate approximately 50% greater than
that of HFCT. Furthermore, Northern blot analyses of ARPKD whole
kidney and western immunoblot of ARPKD cells showed approxi-
mately twofold greater expression of the α-ENaC. These results
suggest that ARPKD cyst lining cells absorb Na+ by a pathway that
involved ENaC activity [205]. Later it was shown that ENaC-mediated
Na+ absorption is up-regulated in a murine ARPKD model epithelium
lacking apical monocilia [202]. Three- to fourfold elevated Isc was
measured inmutant orpk (Oak Ridge PKD)monolayers versus rescued
controls. Examination of this enhanced end point in mutant mono-
layers revealed that that this effect was mediated by ENaC. These data
suggested that ENaC expression and/or function are up-regulated in
the apical membrane of mutant orpk CD principal cell monolayers
[202]. However, Veizis et al. have shown that amiloride sensitive Na+
absorption is decreased in CD cells from the non-orthologous BPK
mouse model of ARPKD [203]. Moreover, they present evidence that
addition of EGF to the apical bathing solution (24 h) led to inhibition
of Na+ transport and decreased ENaC expression in cystic cells and
that this effect was mediated through ERK kinase [204]. Thus, the
authors suggest that the mislocalized apical ErbB receptors are
functionally coupled to the ERK pathway and that abnormal EGF-
dependent regulation of ENaC function and expression may contrib-
ute to PKD pathophysiology [204].
Thus, role of ENaC-mediated sodium absorption and its regulation
by EGF in PKD is obvious. However, several investigations have
reported contradictory results. Thus, the exact mechanism by which
ENaC-mediated sodium transport involved in development and
progression of PKD, and especially ARPKD, is not completely clear.
As indicated by Guay-Woodford [134], although identiﬁed abnormal-
ities in the tubular epithelia diverse and not necessarily reproducible
from one model to another, these abnormalities provide the
framework for evaluating interventions that target speciﬁc processes
and pathways involved in PKD pathogenesis. Hence, investigation of
the modulation of sodium transport by growth factors in PKD models
would facilitate a more complete understanding of the pathologic
development of PKD. Additional studies using cells with endogenous
genotypic and phenotypic effects of PC-1, PC-2 and ﬁbrocystin-1
mutations will be required to understand the role of ENaC in PKD and
EGF-mediated regulation of sodium transport in PKD. Our preliminary
immunohistochemistry analysis revealed that ENaC subunits are
expressed on the apical surface of CDs in PCK rats, the genotypic
model of ARPKD. Moreover, we were able to record ENaC activity with
patch clamp electrophysiology (unpublished observations) in freshly
isolated opened cysts from the PCK rats. However, these observations
require further investigations.
8. Clinical Relevance
ErbB family members are implicated in the development of cardiac
and renal diseases such as cancer, hypertension and ESRD. Therefore,
the therapeutic potential of targeting of ErbB receptors and EGF family
signaling pathways may play key roles in the kidney. A number of
studies have investigated the potential role of EGF and its related
growth factors in acute renal injury and both ADPKD and ARPKD
[4,6,21,58]. Addition of ErbB receptor ligands to epithelial cells
promotes cell proliferation, migration, and epithelial-mesenchymal
cell transdifferentiation. Chronic ErbB activation and mislocalization
are thought to be important in the evolution of PKD. The cyst ﬂuid of
PKD patients contains mitogenic concentrations of ErbB receptor
ligands [109,206–208]. Thus this might represent a protective
mechanism of diseased kidney in PKD.
ADPKD and ARPKD have overlapping but distinct pathogeneses.
Identiﬁcation of the causative mutated genes and elucidation of the
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mediating their regulation will shed new light on these diseases.
Improved understanding of pathogenesis and mechanisms involved
in both ADPKD and ARPKD provide an excellent opportunity for the
development of pathophysiology-based therapies. Some of these have
proven effective in preclinical studies, and clinical trials have begun
[59,209]. Our enhanced understanding of the PKD phenotype at a
cellular level will facilitate identiﬁcation of other interventional
targets.
9. Conclusion
The study of regulation of ion channels and proliferation by ErbB
receptor ligands has expanded considerably in recent years. In vitro
and in vivo studies have provided direct evidence of the role of ErbB
signaling in the kidney. Collectively, these results suggest that ErbB
receptors could be major determinants in the development of renal
lesions, possibly through enhanced cell proliferation and regulation
of sodium reabsorption. However, it is not exactly clear yet how ErbB
receptors ligands affect proliferation and sodium reabsorption in
PKD.
Inappropriate expression, activation and downstream signaling
of ErbB receptors and particularly ErbB2 contribute to the patholog-
ical phenotype of PKD and suggest that inhibition of this pathway
represents a promising therapeutic target in this disease. Undoubt-
edly, many questions remain regarding regulation of sodium
reabsorption and proliferation in normal and PKD cells by ErbB
receptors and their ligands. For example, our data demonstrate that
the ErbB2 receptor is involved in ENaC-mediated sodium transport in
mpkCCDc14 principal cells. It is most likely that ErbB2 forms a
heterodimer with EGFR, although a role for ErbB3 and ErbB4 cannot
be excluded. Neuregulins-1 through -4, which can bind either both
ErbB3 and ErbB4 or only ErbB4 could be utilized in future
experiments to deﬁne any potential involvement of ErbB3 and
ErbB4 in sodium transport. Furthermore, ErbB receptors after
changing their polarity in PKD cells come into close proximity with
ENaC and could thus potentially either form a complex with the
channel or change itsmechanisms of regulation. Future directions for
study will require direct measurements of ENaC channel activity in
response to ErbB family ligands in genotypic ADPKD and ARPKD cell
models.
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